What is B. Riley’s Forecast for Cytokinetics Q1 Earnings?

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Cytokinetics in a research note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings per share of ($1.46) for the quarter. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.34) EPS and FY2029 earnings at $1.06 EPS.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.26 million.

Several other equities analysts have also recently weighed in on the company. Royal Bank of Canada lifted their price objective on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Wednesday, December 18th. Evercore ISI raised Cytokinetics to a “strong-buy” rating in a report on Friday, February 7th. Mizuho boosted their target price on Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Morgan Stanley raised Cytokinetics from an “equal weight” rating to an “overweight” rating and decreased their target price for the stock from $70.00 to $67.00 in a report on Thursday, February 13th. Finally, Stifel Nicolaus began coverage on Cytokinetics in a report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Trading Down 1.4 %

NASDAQ:CYTK opened at $43.27 on Thursday. Cytokinetics has a fifty-two week low of $40.53 and a fifty-two week high of $75.71. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The stock has a market capitalization of $5.12 billion, a PE ratio of -8.04 and a beta of 0.95. The business’s 50-day simple moving average is $46.91 and its 200-day simple moving average is $50.98.

Insiders Place Their Bets

In related news, Director Wendall Wierenga sold 742 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $48.61, for a total transaction of $36,068.62. Following the completion of the sale, the director now owns 24,559 shares of the company’s stock, valued at $1,193,812.99. This trade represents a 2.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Fady Ibraham Malik sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $45.92, for a total value of $91,840.00. Following the sale, the executive vice president now directly owns 116,071 shares of the company’s stock, valued at $5,329,980.32. This represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,822 shares of company stock valued at $874,048 in the last 90 days. Corporate insiders own 3.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Jones Financial Companies Lllp increased its holdings in shares of Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 374 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Cytokinetics during the fourth quarter valued at approximately $29,000. AlphaQuest LLC boosted its position in shares of Cytokinetics by 113,500.0% during the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,135 shares during the last quarter. J.Safra Asset Management Corp boosted its position in shares of Cytokinetics by 62.1% during the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 671 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Cytokinetics by 85.8% during the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 842 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.